Effect of non-oral estrogen on risk markers for metabolic syndrome in early surgically menopausal women
Authors:
- 13 January 2010
- journal article
- research article
- Published by Taylor & Francis in Climacteric
- Vol. 13 (1) , 55-62
Abstract
Objective Postmenopausal women are at an increased risk of cardiovascular disease and metabolic syndrome as many risk factors are aggravated by menopause. Elevated levels of homocysteine, triglyceride and asymmetric dimethylarginine (ADMA) have been recognized as risk factors for metabolic syndrome. The present study aimed to investigate the effect of transdermal estrogen treatment on serum levels of atherogenic amino acids, homocysteine, triglyceride, high density lipoprotein (HDL) cholesterol and ADMA in women with surgical menopause. Methods A prospective study was conducted in 85 surgically menopausal Turkish women at the Department of Menopause of Dr Zekai Tahir Burak Women's Health Research and Education Hospital between March 2007 and March 2008. Subjects were divided into two groups: a treatment group (Group 1) and control (Group 2). Group 1 (n = 46) received transdermal estrogen while Group 2 (n = 39) received no treatment. Body mass index (BMI) and levels of serum homocysteine, ADMA, triglyceride and HDL cholesterol were analyzed postoperatively at the first visit (baseline) and 6th months. Results The two groups did not differ in age, baseline BMI and levels of ADMA, homocysteine and triglyceride. In Group 1, values of serum ADMA, homocysteine, triglyceride and HDL cholesterol levels were not different at baseline and at the 6-month visit (p = 0.996, p = 0.564, p = 0.113 and p = 0.173, respectively). On the other hand, the baseline and the 6th month measurements of serum ADMA, homocysteine and HDL cholesterol levels were significantly different in Group 2 (p = 0.001, p = 0.001, and p = 0.023, respectively). Conclusion Transdermal estrogen treatment has a protective effect against the risk factors of metabolic syndrome (homocysteine, ADMA, HDL cholesterol) in surgically menopausal patients who have undergone surgery in the early premenopausal period.Keywords
This publication has 40 references indexed in Scilit:
- Asymmetric Dimethylarginine Predicts Cardiovascular Events in Patients With Type 2 DiabetesDiabetes Care, 2007
- Asymmetric Dimethylarginine Predicts Major Adverse Cardiovascular Events in Patients With Advanced Peripheral Artery DiseaseArteriosclerosis, Thrombosis, and Vascular Biology, 2006
- Plasma asymmetric dimethylarginine concentrations in newly diagnosed patients with acute myocardial infarction or unstable angina pectoris during two weeks of medical treatmentThe American Journal of Cardiology, 2005
- Endothelial Dysfunction Induced by Hyperhomocyst(e)inemiaCirculation, 2003
- Risk of acute coronary events and serum concentration of asymmetrical dimethylarginineThe Lancet, 2001
- Mild-to-moderate hypertriglyceridemia in young men is associated with endothelial dysfunction and increased plasma concentrations of asymmetric dimethylarginineJACC, 2001
- Does ADMA Cause Endothelial Dysfunction?Arteriosclerosis, Thrombosis, and Vascular Biology, 2000
- Endogenous Nitric Oxide Synthase InhibitorCirculation, 1999
- Asymmetric Dimethylarginine (ADMA): A Novel Risk Factor for Endothelial DysfunctionCirculation, 1998
- Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failureThe Lancet, 1992